ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic s
ZIOPHARM Oncology, Inc. announced guidance today regarding the Company's planned pivotal Phase III trial for palifosfamide in metastatic soft tissue sarcoma, including details of the proposed study's design, timing and regulatory review.